Program
Paclitaxel
Also written as “paclitaxel”, “Paclitaxel Injection” and “IV Paclitaxel”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Neoplasms · Stomach Neoplasms, led by 33 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 160 open or running | phase 3since May 2, 2002 | May 2, 2002 | none ahead |
| Eli Lilly | 140 open or running | phase 3since Nov 6, 2000 | Nov 6, 2000 | none ahead |
| Daehwa Pharmaceutical | 51 open or running | phase 3since Apr 12, 2013 | Apr 12, 2013 | none ahead |
| Achieve Life Sciences | 40 open or running | phase 3since Nov 8, 2005 | Feb 10, 2004 | none ahead |
| Novartis | 40 open or running | phase 3since Jan 4, 2006 | Jan 4, 2006 | none ahead |
| Takeda | 40 open or running | phase 2since Mar 17, 2010 | Mar 17, 2010 | none ahead |
| theradex | 40 open or running | phase 3since Oct 11, 2001 | Nov 1, 1999 | none ahead |
| Boston Scientific | 30 open or running | phase 3since Jan 13, 2017 | May 24, 2007 | none ahead |
| Biocad | 20 open or running | phase 3since Dec 27, 2012 | Dec 27, 2012 | none ahead |
| Ionis Pharmaceuticals | 20 open or running | phase 3since Jun 6, 2001 | Jun 6, 2001 | none ahead |
| Philogen | 20 open or running | phase 2since May 25, 2010 | May 25, 2010 | none ahead |
| Swedish Orphan Biovitrum | 20 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| vascular-biogenics-ltd-operating-as-vbl-therapeutics | 20 open or running | phase 3since Jan 7, 2018 | Oct 18, 2012 | none ahead |
| baker-norton-pharmaceuticals | 10 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| CASI Pharmaceuticals | 10 open or running | phase 2since Nov 13, 2002 | Nov 13, 2002 | none ahead |
| cytran | 10 open or running | phase 2since Jun 6, 2001 | Jun 6, 2001 | none ahead |
| dong-wha-pharmaceutical-co-ltd | 10 open or running | phase 1since Sep 8, 2017 | Sep 8, 2017 | none ahead |
| esperance-pharmaceuticals-inc | 10 open or running | phase 2since Dec 2, 2011 | Dec 2, 2011 | none ahead |
| eurocor-gmbh | 10 open or running | phase 4since Feb 9, 2010 | Feb 9, 2010 | none ahead |
| geron-corporation | 10 open or running | phase 2since Dec 2, 2010 | Dec 2, 2010 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 2since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| Innovent Biologics | 10 open or running | phase 3since Oct 23, 2016 | Oct 23, 2016 | none ahead |
| mabscale-llc | 11 open or running | phase 3since Dec 8, 2022 | Dec 8, 2022 | Dec 2026phase 3 · NCT05654454 |
| matrix-pharmaceutical | 10 open or running | phase 2since Aug 10, 2001 | Aug 10, 2001 | none ahead |
| mercator-medsystems-inc | 10 open or running | no phasesince Feb 13, 2014 | Feb 13, 2014 | none ahead |
| NovoCure | 10 open or running | phase 2since Sep 15, 2014 | Sep 15, 2014 | none ahead |
| oncotech | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| shanghai-huaota-biopharmaceutical-co-ltd | 11 open or running | phase 3since Jan 13, 2026 | Jan 13, 2026 | Apr 10, 2028phase 3 · NCT07360132 |
| shanghai-miracogen-inc | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| tolymph-inc | 11 open or running | phase 2since Nov 13, 2024 | Nov 13, 2024 | Nov 18, 2026phase 2 · NCT06693336 |
| UCB | 10 open or running | phase 2since Sep 6, 2005 | Sep 6, 2005 | none ahead |
| urotronic-inc | 10 open or running | phase 2since Jan 30, 2018 | Jan 30, 2018 | none ahead |
| Zydus Lifesciences | 10 open or running | phase 2since Jan 21, 2000 | Jan 21, 2000 | none ahead |
Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited, Eisai, parexel, Daiichi Sankyo, baili-bio-chengdu-pharmaceutical-co-ltd, Arcus Biosciences, Ono Pharmaceutical, compass-therapeutics, abl-bio-inc, wuxi-cds-clinical-research-shanghai-co-ltd, Valerio Therapeutics, immatics-biotechnologies-gmbh, Teva Pharmaceutical Industries, Johnson & Johnson and medarex.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 47 studies since Nov 8, 2005.
- Jan 13, 2017Phase 3 study in Peripheral Arterial DiseaseBoston Scientific · NCT03064126 · 440 enrolled · United States, Austria, Belgium and more
- Sep 8, 2017dong-wha-pharmaceutical-co-ltd's first study: phase 1 study in Advanced Breast CancerNew to dong-wha-pharmaceutical-co-ltddong-wha-pharmaceutical-co-ltd · NCT03282825 · 18 enrolled · Korea, Republic of
- Sep 28, 2017Phase 3 study in RecurrenceDaehwa Pharmaceutical · NCT03315364 · 549 enrolled · Bulgaria, China, Hungary and more
- Oct 19, 2017Phase 2 study in RecurrenceDaehwa Pharmaceutical · NCT03326102 · 72 enrolled · United States, Czechia
- Jan 7, 2018Phase 3 study in Ovarian Neoplasmsvascular-biogenics-ltd-operating-as-vbl-therapeutics · NCT03398655 · 408 enrolled · United States, Israel, Japan and more
- Jan 30, 2018urotronic-inc's first study: phase 2 study in Prostatic HyperplasiaNew to urotronic-incurotronic-inc · NCT03423979 · 80 enrolled · Dominican Republic, Panama
- Oct 9, 2018Phase 2 study in Stomach NeoplasmsBristol-Myers Squibb · NCT03704077 · United States, Argentina, Australia and more
- Nov 23, 2020Phase 1 study in Advanced Solid TumorDaehwa Pharmaceutical · NCT04675528 · 25 enrolled · Hungary
- Nov 4, 2022Phase 2 study in Ovarian NeoplasmsBristol-Myers Squibb · NCT05613088 · 106 enrolled · United States, Australia, Belgium and more
- Dec 8, 2022mabscale-llc's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to mabscale-llcmabscale-llc · NCT05654454 · 620 planned · Russian Federation
- Feb 22, 2023shanghai-miracogen-inc's first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to shanghai-miracogen-incshanghai-miracogen-inc · NCT05754853 · 290 planned · China
- Nov 13, 2024tolymph-inc's first study: phase 2 study in CarcinomaNew to tolymph-inctolymph-inc · NCT06693336 · 42 planned · United States, Canada
- Jan 13, 2026shanghai-huaota-biopharmaceutical-co-ltd's first study: phase 3 study in Squamous Non-small Cell Lung CancerNew to shanghai-huaota-biopharmaceutical-co-ltdshanghai-huaota-biopharmaceutical-co-ltd · NCT07360132 · 480 planned · China
- Oct 28, 2026Phase 2 study terminatedStudy stoppedNCT05613088 · “Business objectives have changed.”
Ahead
- Nov 18, 2026Primary completion: phase 2 study in Carcinomatolymph-inc · NCT06693336
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell Lungmabscale-llc · NCT05654454
- Apr 10, 2028Primary completion: phase 3 study in Squamous Non-small Cell Lung Cancershanghai-huaota-biopharmaceutical-co-ltd · NCT07360132
TargetBeta
“Tubulin inhibitor”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Docetaxelrule | Sanofi | phase 4 | 199 |
| cabazitaxelrule | Sanofi | phase 4 | 21 |
| Vinblastinerule | Takeda | phase 4 | 4 |
| desoxyepothilone Brule | beijing-biostar-pharmaceuticals-co-ltd | phase 3 | 19 |
| plinabulinrule | beyondspring-pharmaceuticals-inc | phase 3 | 8 |
Studies
The newest 60 of 84 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07360132Squamous Non-small Cell Lung Cancer · China | 3 | Not yet recruiting | shanghai-huaota-biopharmaceutical-co-ltd | Apr 10, 2028 | 480 |
| NCT06693336Carcinoma · United States, Canada | 2 | Recruiting | tolymph-inc | Nov 18, 2026 | 42 |
| NCT05754853Advanced or Metastatic Urothelium Cancer · China | 3 | Recruiting | shanghai-miracogen-inc | Oct 2025 | 290 |
| NCT05654454Carcinoma, Non-Small-Cell Lung · Russian Federation | 3 | Recruiting | mabscale-llc | Dec 2026 | 620 |
| NCT05613088Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Jun 17, 2024 | 106 |
| NCT04675528Advanced Solid Tumor · Hungary | 1 | Completed | Daehwa Pharmaceutical | Dec 12, 2022 | 25 |
| NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Withdrawn | Bristol-Myers Squibb | Feb 27, 2022 | 0 |
| NCT03423979Prostatic Hyperplasia · Dominican Republic, Panama | 2 | Completed | urotronic-inc | Jun 4, 2019 | 80 |
| NCT03398655Ovarian Neoplasms · United States, Israel, Japan and more | 3 | Completed | vascular-biogenics-ltd-operating-as-vbl-therapeutics | Jul 19, 2022 | 408 |
| NCT03326102Recurrence · United States, Czechia | 2 | Completed | Daehwa Pharmaceutical | Dec 13, 2022 | 72 |
| NCT03315364Recurrence · Bulgaria, China, Hungary and more | 3 | Active, not recruiting | Daehwa Pharmaceutical | Feb 19, 2024 | 549 |
| NCT03282825Advanced Breast Cancer · Korea, Republic of | 1 | UNKNOWN | dong-wha-pharmaceutical-co-ltd | Feb 2018 | 18 |
| NCT03064126Peripheral Arterial Disease · United States, Austria, Belgium and more | 3 | Completed | Boston Scientific | Nov 18, 2019 | 440 |
| NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Sep 8, 2021 | 505 |
| NCT02954172NSCLC · China | 3 | Completed | Innovent Biologics | Oct 19, 2018 | 450 |
| NCT02890511Stomach Neoplasms · Korea, Republic of | 2 | Completed | Daehwa Pharmaceutical | Oct 2012 | 28 |
| NCT02725268Endometrial Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Takeda | Jul 2, 2019 | 241 |
| NCT02539225Metastatic Gastric Adenocarcinoma · Japan, Korea, Republic of, Taiwan | 2 | Completed | Eli Lilly | Oct 25, 2017 | 191 |
| NCT02514551Stomach Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Oct 27, 2017 | 245 |
| NCT02477826Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Oct 25, 2024 | 2,747 |
| NCT02412722Non-hematologic Malignancy · United States | 1 | Completed | Takeda | May 31, 2018 | 61 |
| NCT02244502Ovarian Neoplasms · Belgium, Germany, Spain and more | 2 | UNKNOWN | NovoCure | Dec 2016 | 31 |
| NCT02066103Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer · United States | – | Completed | mercator-medsystems-inc | Jun 2016 | 20 |
| NCT02054884Carcinoma, Merkel Cell · Austria, Denmark, France and more | 2 | Terminated | Philogen | Dec 31, 2016 | 13 |
| NCT01953536Breast Neoplasms | 2 | Withdrawn | Novartis | Nov 2016 | 0 |
| NCT01839773Stomach Neoplasms · Korea, Republic of | 3 | Completed | Daehwa Pharmaceutical | Aug 2015 | 238 |
| NCT01764022Breast Neoplasms · Belarus, India, Russian Federation and more | 3 | Completed | Biocad | Mar 2015 | 225 |
| NCT01763645Carcinoma, Non-Small-Cell Lung · Belarus, India, Russian Federation and more | 3 | Completed | Biocad | Nov 2014 | 353 |
| NCT01711970Platinum Resistant Ovarian Cancer · United States | 2 | Completed | vascular-biogenics-ltd-operating-as-vbl-therapeutics | May 3, 2017 | 38 |
| NCT01497470Neoplasms · United States | 1 | Completed | Achieve Life Sciences | Jul 2013 | 36 |
| NCT01491217Stomach Neoplasms · Korea, Republic of | 2 | UNKNOWN | Hanmi Pharmaceutical | Mar 2012 | 53 |
| NCT01485848Ovarian Cancer Recurrent · United States | 2 | Completed | esperance-pharmaceuticals-inc | May 2014 | 49 |
| NCT01351350Hematologic Neoplasms · United States | 1 | Completed | Takeda | Sep 15, 2017 | 68 |
| NCT01256762Breast Neoplasms · United States, Canada | 2 | Completed | geron-corporation | Oct 2012 | 166 |
| NCT01234038Carcinoma, Non-Small-Cell Lung · United States, Hungary, Poland and more | 2 | Completed | Ionis Pharmaceuticals | Oct 2012 | 116 |
| NCT01134250Breast Neoplasms · Italy | 2 | Completed | Philogen | Apr 7, 2014 | 48 |
| NCT01091428Ovarian Neoplasms · United States | 2 | Completed | Takeda | Aug 12, 2014 | 191 |
| NCT01066832Instent Restenosis · Germany, Italy, Netherlands | 4 | Completed | eurocor-gmbh | Dec 2010 | 276 |
| NCT01024101Head and Neck Neoplasms | 2 | Completed | Bristol-Myers Squibb | Dec 2005 | 36 |
| NCT01024062Carcinoma, Non-Small-Cell Lung | 2 | Completed | Bristol-Myers Squibb | Mar 2005 | 60 |
| NCT01023204Breast Neoplasms | 2 | Completed | Bristol-Myers Squibb | Jul 2005 | 68 |
| NCT00971945Breast Neoplasms · Japan | 2 | Completed | Bristol-Myers Squibb | Mar 31, 2008 | 6 |
| NCT00971867Head and Neck Neoplasms · Japan | 2 | Completed | Bristol-Myers Squibb | Nov 26, 2008 | 11 |
| NCT00971841Esophageal Neoplasms | 2 | Completed | Bristol-Myers Squibb | Apr 2012 | 1 |
| NCT00855764Head and Neck Neoplasms | 2 | Completed | Bristol-Myers Squibb | Oct 2006 | 36 |
| NCT00796991Advanced Melanoma · United States | 1 | Completed | Bristol-Myers Squibb | Nov 2009 | 72 |
| NCT00788931Breast Neoplasms · United States, Australia, Belgium and more | 1 | Completed | Novartis | Aug 2010 | 15 |
| NCT00573131Esophageal Neoplasms · United States, Czechia, India and more | 2 | Terminated | Boston Scientific | Nov 2010 | 137 |
| NCT00490711Carcinoma, Ovarian Epithelial · Slovakia | 2 | Completed | Eli Lilly | 7 | |
| NCT00479765Glioblastoma · United States | 2 | Terminated | Boston Scientific | Oct 2009 | 4 |
| NCT00394251Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Mar 1, 2007 | 197 |
| NCT00344552Esophageal Neoplasms · Japan | 2 | Completed | Bristol-Myers Squibb | Mar 2008 | 53 |
| NCT00343291Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Eli Lilly | May 2010 | 121 |
| NCT00337532Head and Neck Neoplasms · Korea, Republic of | 3 | Completed | Bristol-Myers Squibb | Jun 2007 | 50 |
| NCT00334802Breast Neoplasms · Japan | 2 | Completed | Eli Lilly | Feb 2008 | 62 |
| NCT00316199Breast Neoplasms · China | 2 | Completed | Eli Lilly | Apr 2008 | 60 |
| NCT00281658Breast Neoplasms · Brazil, China, Hong Kong and more | 3 | Completed | Novartis | Jun 18, 2010 | 444 |
| NCT00272987Breast Neoplasms · United States, Belgium | 3 | Terminated | Novartis | Jul 31, 2009 | 63 |
| NCT00269828Carcinoma, Non-Small-Cell Lung · United States, Argentina, Bulgaria and more | 3 | Terminated | Swedish Orphan Biovitrum | 600 | |
| NCT00251095Breast Neoplasms · United States | 3 | Terminated | Achieve Life Sciences | Sep 2007 | 821 |
How it is read
Names in the registry
- “Paclitaxel”, 114 entries
- “paclitaxel”, 46 entries
- “Paclitaxel Injection”, 3 entries
- “IV Paclitaxel”, 2 entries
- “TOCOSOL Paclitaxel”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 48 studies
- Carcinoma, Non-Small-Cell Lung, 44 studies
- Ovarian Neoplasms, 19 studies
- Neoplasms, 9 studies
- Stomach Neoplasms, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.